Conduit Pharmaceuticals Stock Shares Outstanding

CDT Stock

0.11 0.01 11.00%

Conduit Pharmaceuticals fundamentals help investors to digest information that contributes to Conduit Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Conduit Stock. The fundamental analysis module provides a way to measure Conduit Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Conduit Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

Common Stock Shares Outstanding is likely to drop to about 37.6 M in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Conduit Pharmaceuticals Company Shares Outstanding Analysis

Conduit Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Conduit Pharmaceuticals Shares Outstanding

116.8 M

Most of Conduit Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Conduit Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Conduit Shares Outstanding Driver Correlations

Understanding the fundamental principles of building solid financial models for Conduit Pharmaceuticals is extremely important. It helps to project a fair market value of Conduit Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Conduit Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Conduit Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Conduit Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Long Term Debt	Total Liab	Net Invested Capital	Total Current Assets	Short Term Debt	Common Stock	Deferred Long Term Liab	Short Long Term Debt	Net Working Capital	Intangible Assets
Total Assets		0.9	-0.69	-0.99	-0.82	0.7	0.52	0.95	1.0	1.0	-0.13	-0.95	0.95	1.0	-0.95
Total Stockholder Equity	0.9		-0.3	-0.95	-0.48	0.36	0.09	0.99	0.85	0.89	-0.55	-0.83	0.85	0.89	-0.83
Net Tangible Assets	-0.69	-0.3		0.57	0.98	-0.94	-0.97	-0.43	-0.76	-0.71	-0.63	0.69	-0.66	-0.71	0.69
Net Debt	-0.99	-0.95	0.57		0.72	-0.61	-0.37	-0.99	-0.97	-0.98	0.28	0.92	-0.95	-0.98	0.92
Retained Earnings	-0.82	-0.48	0.98	0.72		-0.94	-0.91	-0.6	-0.87	-0.83	-0.47	0.8	-0.78	-0.83	0.8
Long Term Debt	0.7	0.36	-0.94	-0.61	-0.94		0.86	0.48	0.76	0.71	0.55	-0.59	0.78	0.72	-0.59
Total Liab	0.52	0.09	-0.97	-0.37	-0.91	0.86		0.22	0.59	0.53	0.77	-0.55	0.47	0.53	-0.55
Net Invested Capital	0.95	0.99	-0.43	-0.99	-0.6	0.48	0.22		0.92	0.94	-0.43	-0.89	0.9	0.94	-0.89
Total Current Assets	1.0	0.85	-0.76	-0.97	-0.87	0.76	0.59	0.92		1.0	-0.04	-0.95	0.95	1.0	-0.95
Short Term Debt	1.0	0.89	-0.71	-0.98	-0.83	0.71	0.53	0.94	1.0		-0.11	-0.95	0.95	1.0	-0.95
Common Stock	-0.13	-0.55	-0.63	0.28	-0.47	0.55	0.77	-0.43	-0.04	-0.11		0.1	-0.1	-0.1	0.1
Deferred Long Term Liab	-0.95	-0.83	0.69	0.92	0.8	-0.59	-0.55	-0.89	-0.95	-0.95	0.1		-0.81	-0.95	1.0
Short Long Term Debt	0.95	0.85	-0.66	-0.95	-0.78	0.78	0.47	0.9	0.95	0.95	-0.1	-0.81		0.96	-0.81
Net Working Capital	1.0	0.89	-0.71	-0.98	-0.83	0.72	0.53	0.94	1.0	1.0	-0.1	-0.95	0.96		-0.95
Intangible Assets	-0.95	-0.83	0.69	0.92	0.8	-0.59	-0.55	-0.89	-0.95	-0.95	0.1	1.0	-0.81	-0.95

Click cells to compare fundamentals

Conduit Shares Outstanding Historical Pattern

Today, most investors in Conduit Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Conduit Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Conduit Pharmaceuticals shares outstanding as a starting point in their analysis.

Conduit Pharmaceuticals Shares Outstanding

Timeline

Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

Competition

Predict Conduit Pharmaceuticals

Common Stock Shares Outstanding Over Time

Based on the latest financial disclosure, Conduit Pharmaceuticals has 116.8 M of shares currently outstending. This is 35.3% lower than that of the Life Sciences Tools & Services sector and 9.3% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 79.57% higher than that of the company.

Conduit Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Conduit Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Conduit Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Conduit Pharmaceuticals by comparing valuation metrics of similar companies.

Conduit Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.

Conduit Fundamentals

	Return On Asset	-3.22
	Current Valuation	14.98 M
	Shares Outstanding	116.8 M
	Shares Owned By Insiders	49.11 %
	Shares Owned By Institutions	4.05 %
	Number Of Shares Shorted	2.36 M
	EBITDA	(324 K)
	Net Income	(535 K)
	Total Debt	985 K
	Book Value Per Share	(0.01) X
	Cash Flow From Operations	(7.72 M)
	Short Ratio	0.14 X
	Earnings Per Share	(0.23) X
	Beta	2.12
	Market Capitalization	12.46 M
	Total Asset	7.22 M
	Retained Earnings	(11.3 M)
	Working Capital	3.93 M
	Net Asset	7.22 M

About Conduit Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Conduit Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Conduit Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Conduit Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Conduit Stock Analysis

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC